# Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Canonical URL: https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-closing-of-oversubscribed-30-million-private-placement
Ticker: APRE
Company: Aprea Therapeutics
Source: Aprea Therapeutics
Published: 2026-04-01 12:31 EST
Original Source URL: https://ir.aprea.com
## Summary

Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is well suited DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision

## Article Body
Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is well suited DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision
## Recent Company News
- 2026-06-01 12:00 EST — [Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors](https://biopharmsignal.com/news/APRE/aprea-therapeutics-presents-updated-phase-1-data-on-wee1-inhibitor-apr-1051-at-asco-2026-demonstrating-early-monotherapy-activity-and-manageable-tolerability-in-advanced-solid-tumors) — Source: Aprea Therapeutics
- 2026-05-13 10:30 EST — [Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/APRE/aprea-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update) — Source: Aprea Therapeutics
- 2026-04-21 14:15 EST — [Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting](https://biopharmsignal.com/news/APRE/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting) — Source: Aprea Therapeutics
- 2026-04-01 12:31 EST — [Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement](https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-closing-of-oversubscribed-30-million-private-placement) — Source: Aprea Therapeutics
- 2026-03-30 12:01 EST — [Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement](https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-oversubscribed-30-million-private-placement) — Source: Aprea Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)